|
Neonatal Intensive Care Drug Manual
|
| bet | 476/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Piperacillin/Tazobactam
Revision Date : 16-11-2020
|
Approved: TC, KOH
|
Alert
|
The Antimicrobial Stewardship Team has listed this drug under the following categories:
Restricted.
|
Indication
|
Therapy of non-CNS systemic infections, necrotising enterocolitis and intra-abdominal infections caused by susceptible Gram positive and Gram negative bacteria including anaerobes and many Enterobacterales and Pseudomonas spp.(1)
Susceptibility of coagulase-negative staphylococci (CONS) is generally not tested though oxacillin-resistant CONS should be considered resistant and piperacillin-tazobactam should not be used as first-line for suspected CONS sepsis.(2)
|
Action
|
β-lactam/β-lactamase inhibitor combination with a broad spectrum of antibacterial activity encompassing Gram-positive and Gram-negative aerobic bacteria and anaerobic bacteria, including many pathogens producing β-lactamases.(1) Piperacillin component is a semi synthetic penicillin that inhibits septum and cell wall synthesis of susceptible bacteria. Tazobactam is a beta lactamase inhibitor that enhances the antibiotic spectrum of piperacillin.
|
Drug type
|
Antibiotic – ureidopenicillin and beta-lactamase inhibitor.
|
Trade name
|
Piperacillin/Tazobactam Kabi, Tazocin EF, PiperTaz, Piptaz, PipTaz-AFT, Tazopip
|
Presentation
|
4.5 g vial (4 g piperacillin and 0.5 g tazobactam).
|
Dose
|
Dose based on piperacillin component (3, 4)
|
|
| |
